Neovacs SA (ALNEV) Stock Statistics & Valuation Metrics

Neovacs SA has a market cap or net worth of €203.60K. The enterprise value is -€204.98K.

Neovacs SA has 159,064 shares outstanding. The number of shares has decreased by -2.65% in one year.

Neovacs SA’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -24.64%.

The current PE Ratio of Neovacs SA is ―. Neovacs SA’s PEG ratio is 6.65.

In the last 12 months, Neovacs SA had revenue of 161.78K and earned -4.90M in profits. Earnings per share was -0.13.

In the last 12 months, operating cash flow was -2.60M and capital expenditures -1.18K, giving a free cash flow of -2.60M billion.

Neovacs SA pays an annual dividend of ―, resulting in a dividend yield of ―

Neovacs SA upcoming earnings date is Oct 22, 2026, Before Open (Confirmed).

Neovacs SA as a current ratio of 0.84, with Debt / Equity ratio of 2.98%

In the past 12 months, Neovacs SA has paid -628.70K in taxes.

Neovacs SA EV to EBITDA ratio is -621.56, with an EV/FCF ratio of -646.50.

Neovacs SA has €571.79K in cash and marketable securities with €537.20K in debt, giving a net cash position of €34.59K billion.

Gross margin is -2796.53%, with operating margin of -3354.77%, and net profit margin of -3026.84%.

The average price target for Neovacs SA is ―, which is 11.43% higher than the current price. The consensus rating is ―